Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Breast cancer, metastatic 1

273O - nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer


19 Sep 2020


Proffered Paper - Breast cancer, metastatic 1


Targeted Therapy;  Immunotherapy

Tumour Site

Breast Cancer


Erika Hamilton


Annals of Oncology (2020) 31 (suppl_4): S348-S395. 10.1016/annonc/annonc268


E.P. Hamilton1, J. Cortés2, O. Ozyilkan3, S. Chen4, K. Petrakova5, A. Manikhas6, G. Jerusalem7, R. Hegg8, J. Huober9, S.C. Chapman10, Z. Yang10, Y. Chen10, E.L. Johnston10, M. Martin11

Author affiliations

  • 1 Drug Development Unit, Sarah Cannon Research Institute-Cancer Centre, 37203 - Nashville/US
  • 2 Oncology Department, Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 3 Medical Oncology Dept., Baskent Universitesi Adana Uygulama Ve Arastirma Merkezi - Faculty of Medicine, 1120 - Adana/TR
  • 4 Breast Surgery Division, Chang Gung Memorial Hospital - Linkou, Taiwan/CN
  • 5 Medical Oncology Department, Masaryk Memorial Cancer Institute, 656 53 - Brno/CZ
  • 6 Medical Oncology, City Clinical Oncology Dispensary, 198255 - Saint-Petersburg/RU
  • 7 Medical Oncology Department, Centre Hospitalier Universitaire Sart Tilman, 4000 - Liège/BE
  • 8 Medical Oncology, Gynecological Clinical Service School of Medicine, Univ. Sao Paulo, 04524-003 - Sao Paulo/BR
  • 9 Dept Of Gynecology, Breast Center, Universitaetsfrauenklinik Ulm, 89075 - Ulm/DE
  • 10 Oncology, Eli Lilly and Company, 46225 - Indianapolis/US
  • 11 Oncology, Instituto de Investigación Sanitaria Gregorio Marañon, Madrid/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 273O


Abemaciclib, an oral, continuously dosed cyclin-dependent kinase 4 & 6 (CDK 4 & 6) inhibitor, improves progression free survival (PFS) in combination with endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), metastatic breast cancer (MBC) in the phase III MONARCH2 and 3 studies. In the phase II nextMONARCH study, primary analysis of PFS and ORR confirmed the robust single-agent activity of abemaciclib in heavily pretreated HR+, HER2- MBC with no significant improvement by addition of tamoxifen. We here report the final 24-month overall survival results.


nextMONARCH was a multicenter, randomized, open-label phase II trial of abemaciclib in women with heavily pretreated HR+, HER2- MBC whose disease progressed on or after ET and chemotherapy. Patients were randomized 1:1:1 to abemaciclib 150 mg + tamoxifen 20 mg (A+T), or abemaciclib 150 mg (A-150) or abemaciclib 200 mg plus prophylactic loperamide (A-200). Final OS analysis occurred 24 months after the last patient entered treatment. OS was a preplanned secondary endpoint.


At the time of data cutoff (28-June-2019), 12 of the 234 patients enrolled were still ongoing on study treatment. Median follow-up was 27.2 months. Median OS was 24.2 months in the A+T arm, compared to 20.8 months in A-150, and 17.0 months in A-200 (A+T vs. A-150: HR 0.620 (95% CI [0.397, 0.969] p=0.034); A-150 vs. A-200: HR 0.956 (95% CI [0.635, 1.438] p=0.832)). The primary PFS endpoint and ORR were unchanged at the 24-month analysis. Common treatment-emergent adverse events (TEAEs) across all abemaciclib arms occurring in ≥25% of patients included diarrhea (61.1%), neutropenia (49.6%), anemia (40.6%), nausea (36.3%), leukopenia (30.8%), fatigue (29.9%) and abdominal pain (27.4%).


Addition of tamoxifen to abemaciclib provided a statistically significant median OS improvement compared to abemaciclib monotherapy in this heavily pretreated HR+, HER2- MBC patient population. PFS was consistent with the primary results of nextMONARCH with no significant difference. No new safety findings were observed.

Clinical trial identification


Editorial acknowledgement

Nicholas Pulliam, PhD - Eli Lily and Company.

Legal entity responsible for the study

Eli Lilly and Company.


Eli Lilly and Company.


E.P. Hamilton: Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Fred Hutchinson; Research grant/Funding (institution): OncoMed; Research grant/Funding (institution): MedImmune; Research grant/Funding (institution): StemCentrx; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Curis; Research grant/Funding (institution): Verastem; Research grant/Funding (institution): Zymeworks; Research grant/Funding (institution): Syndax; Research grant/Funding (institution): Lycera; Research grant/Funding (institution): Rgenix; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Mersana; Research grant/Funding (institution): Millenium; Research grant/Funding (institution): TapImmune; Research grant/Funding (institution): Cascadian; Research grant/Funding (institution): Eli Lilly and Company; Research grant/Funding (institution): BerGenBio; Research grant/Funding (institution): Medication; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Tesaro; Research grant/Funding (institution): Kamdon; Research grant/Funding (institution): BI; Research grant/Funding (institution): Eisai; Research grant/Funding (institution): H3 Biomedicines; Research grant/Funding (institution): Radius; Research grant/Funding (institution): Acerta; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Macrogenics. J. Cortés: Research grant/Funding (institution): Puma C; Honoraria (self), Advisory/Consultancy: Celgene; Advisory/Consultancy: Cellestia; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy: Biothera Pharmaceutical; Advisory/Consultancy: Merus; Advisory/Consultancy: Seattle Genetics; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Advisory/Consultancy: Erytech; Advisory/Consultancy: Athenex; Advisory/Consultancy: Polyphor; Honoraria (self), Advisory/Consultancy: Eli Lilly and Company; Advisory/Consultancy: Servier; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Sharp&Dohme; Advisory/Consultancy: GSK; Advisory/Consultancy: Leuko; Advisory/Consultancy: Bioasis; Advisory/Consultancy: Clovis Oncology; Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Eisai; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Honoraria (self): Samsung Bioepis; Research grant/Funding (institution): Ariad Pharmaceuticals; Research grant/Funding (institution): Baxalta GMBH/Servier Affaires; Research grant/Funding (institution): Bayer Healthcare; Research grant/Funding (institution): Guardanth Health; Research grant/Funding (institution): Piqur Therapeutics. K. Petrakova: Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): BMS. G. Jerusalem: Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Lilly; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Honoraria (institution), Research grant/Funding (self), Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Celgene; Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: Puma Biotechnology. J. Huober: Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Pfizer; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Celgene; Advisory/Consultancy: Hexal; Travel/Accommodation/Expenses: Daiichi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.